Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Silence Therapeutics and InteRNA Technologies enter miRNA agreement

Sep. 12, 2011

Taiho sets date for Japanese launch of Zolinza

Sep. 12, 2011

Peregrine Pharmaceuticals completes enrollment in phase II bavituximab trial

Sep. 12, 2011

Ongoing ALTTO study modified

Sep. 12, 2011

Genentech discloses new brain-penetrant PI3K inhibitors

Sep. 12, 2011

ME-143 enters clinical development

Sep. 9, 2011

Alchemia opens recruitment in phase II HA-irinotecan trial

Sep. 9, 2011

FDA clears DelMar Pharmaceuticals' IND for phase I/II VAL-083 trial

Sep. 9, 2011

Novel recombinant proteins catalyze tRNA aminoacylation

Sep. 9, 2011

Novartis develops novel cyclin-dependent kinase inhibitors

Sep. 9, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...